Product Reports Resources Pricing Login Book a demo

Kite Pharma

Biotech & Life Sciences · Santa Monica, United States · Founded 2009 · IPO 2014

Immune-based therapies to treat cancer indications

Valuation $12B
Revenue $20M
Power Law Decacorn$10B+ valuation tier

Talent graph

Kite Pharma's talent

Book a demo to see the people
Employees mapped 4,029 incl. 16 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on Kite Pharma's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Two River
Riverbank Capital Securities
Lee Linden
Alta Partners
Series B+ 5 investors entered at this stage
National Cancer Institute (NCI)
Arie Belldegrun
Weizmann Institute of Science
University of California
Los Angeles

Global footprint

Where Kite Pharma has talent and traffic

Workforce by country
33 countries with
team presence
🇺🇸 United States66.6%
🇳🇱 Netherlands24.4%
🇬🇧 United Kingdom2.4%
🇪🇸 Spain0.9%
🇮🇪 Ireland0.9%
Top 5 of 33 shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States60.5%
🇳🇱 Netherlands12.5%
🇬🇧 United Kingdom9.5%
🇮🇳 India6.5%
🇵🇭 Philippines4%
Top 5 markets shown

Patent intelligence

$199M patent portfolio · 176 active families

Estimated portfolio value
$199M
1.7% of market cap · comparable to top peer Autolus ($150M)
176 active patent families
Where Kite Pharma innovates Antigen bindingAntigen receptorsCancer researchCell biologyCell therapy

Where Kite Pharma concentrates vs peers

Each axis is a top-10 topic across Kite Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Kite Pharma's 14 investments and acquisitions.

Every disclosed deal where Kite Pharma appeared as a backer or acquirer, 2016–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

14 deals across Kite Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Kite Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        14 of 14 deals

        Market sentiment

        What the market is saying about Kite Pharma

        An AI-synthesized read of the highest-engagement posts about Kite Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Kite Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles